Burning Rock Biotech (NASDAQ:BNR) Stock Price Down 3.7% - What's Next?

Key Points

• Burning Rock Biotech shares fell 3.7% to about $9.56 in mid-day trading, with volume 54% below the average. The stock has a market capitalization of roughly $100.6 million and trades well below its 200-day moving average.
• Analyst sentiment remains negative: Weiss Ratings downgraded the stock to “sell,” Wall Street Zen moved it to “hold,” and MarketBeat reports a consensus “Sell” rating.
• The company beat quarterly EPS expectations, reporting a loss of $0.20 per share versus the expected $2.29 loss, but revenue of $15.66 million missed estimates of $19.21 million. Insiders have continued buying shares, purchasing 731,410 shares worth about $6.18 million over the past 90 days.

Shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR - Get Free Report) traded down 3.7% during mid-day trading on Thursday . The company traded as low as $9.29 and last traded at $9.5580. 2,971 shares changed hands during mid-day trading, a decline of 54% from the average daily volume of 6,448 shares. The stock had previously closed at $9.93.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Weiss Ratings cut shares of Burning Rock Biotech from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, July 31st. Wall Street Zen cut shares of Burning Rock Biotech from a "buy" rating to a "hold" rating in a report on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Sell".

Burning Rock Biotech Trading Down 3.7%

The company has a market capitalization of $100.55 million, a P/E ratio of -11.66 and a beta of 1.34. The company has a 50-day simple moving average of $9.15 and a 200 day simple moving average of $16.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last announced its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.29) by $2.09. The firm had revenue of $15.66 million for the quarter, compared to analyst estimates of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Insider Buying and Selling

In other news, Director Yusheng Han bought 24,900 shares of the stock in a transaction on Friday, June 26th. The stock was purchased at an average price of $8.00 per share, for a total transaction of $199,200.00. Following the acquisition, the director owned 18,404,086 shares in the company, valued at approximately $147,232,688. This trade represents a 0.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last 90 days, insiders have purchased 731,410 shares of company stock worth $6,182,660. Company insiders own 30.30% of the company's stock.

Institutional Trading of Burning Rock Biotech

A number of large investors have recently added to or reduced their stakes in the company. Crcm LP boosted its holdings in shares of Burning Rock Biotech by 121.8% during the 4th quarter. Crcm LP now owns 491,426 shares of the company's stock worth $9,902,000 after buying an additional 269,851 shares during the period. Renaissance Technologies LLC raised its holdings in Burning Rock Biotech by 13.8% in the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company's stock valued at $571,000 after acquiring an additional 4,290 shares during the period. Prospera Financial Services Inc raised its holdings in Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company's stock valued at $628,000 after acquiring an additional 6,430 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Burning Rock Biotech during the fourth quarter worth approximately $220,000. Institutional investors and hedge funds own 30.03% of the company's stock.

About Burning Rock Biotech

Burning Rock Biotech NASDAQ: BNR is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company's core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source